Director Todd Shegog filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting no securities beneficially owned in InMed Pharmaceuticals Inc. as of the event date of November 6, 2026.

Key Highlights

  • Reporting person: Todd Shegog, identified as a Director of InMed Pharmaceuticals Inc. (NASDAQ:MTRI).
  • Event date: The date of the event requiring the statement is listed as November 6, 2026.
  • No securities held: The filing states "No securities are beneficially owned" in both Table I (non-derivative) and Table II (derivative) sections.
  • Filing date: The form was signed and filed on November 12, 2026, by Jerad G. Seurer as attorney-in-fact for Todd Shegog.
  • Filing type: This is an initial statement, not an amendment to a prior filing.

InMed Pharmaceuticals Director Todd Shegog Reports Zero Initial Holdings

According to the filing, Todd Shegog submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - in connection with his role as a Director of InMed Pharmaceuticals Inc., traded on NASDAQ under the symbol MTRI. The statement was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain beneficial owners to report their initial holdings upon becoming a reporting person.

The filing discloses that as of the event date of November 6, 2026, Shegog held no securities of InMed Pharmaceuticals, either directly or indirectly. Table I, covering non-derivative securities, and Table II, covering derivative securities such as options, warrants, or convertible instruments, are both unpopulated. The filing includes the remark that "No securities are beneficially owned."

The form was signed on November 12, 2026, by Jerad G. Seurer acting as attorney-in-fact for Todd Shegog under a power of attorney listed as Exhibit 24. Shegog's listed address is care of Mentari Therapeutics, Inc., 221 Crescent St., Building 23, Suite 105, Waltham, Massachusetts 02453.

What Was Disclosed

Todd Shegog, a newly reporting Director of InMed Pharmaceuticals Inc. (NASDAQ:MTRI), filed an initial beneficial ownership statement on November 12, 2026, disclosing that he held no direct or indirect securities in the company as of November 6, 2026.